cytokine release syndrome
Chronic Disease Management? CASTLE Unveils CAR‑T Risks?
In the CASTLE trial, about one in ten participants experienced cytokine release syndrome (CRS), signalling that CAR-T therapy demands a dedicated monitoring plan within chronic disease management. Seventeen percent of CASTLE participants experienced CRS, prompting a dedicated monitoring schedule that now informs how clinicians handle treatment-refractory autoimmune conditions. Medical Disclaimer: